Clinuvel Pharmaceuticals Ltd (OTC Pink - Current Information:CLVLY)
| 2.98 Data as of 10:58am ET |  +0.01 / +0.34%Today’s Change | 1.10 Today|||52-Week Range 5.00 | -12.81% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $125.9M |
Company Description
Clinuvel Pharmaceuticals Ltd. operates as a global biopharmaceutical company. It is focused on the development of SCENESSE, its proprietary photoprotective drug. The company also focuses on developing drugs for the treatment of severe skin disorders. Clinuvel Pharmaceuticals was founded on December 14, 1999 and is headquartered in Melbourne, Australia.
Contact Information
Clinuvel Pharmaceuticals Ltd. 190 Queen Street Melbourne Victoria (vic) 3000 |
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| Philippe J. Wolgen | Chief Executive Officer, Director & MD |
| Darren M. Keamy | Chief Financial Officer & Secretary |
| Dennis J. Wright | Chief Scientific Officer |
| Lachlan Hay | Media Relations |
.